Biggest News Aggregation in the World
📰 Upper Limit News

Page 4 - Upper Limit News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Upper Limit. Real-time updates on events, politics, business and more.

Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023
United States Jula Inrig Naomi Eichenbaum Nivi Nehra Deric Dube Corporate Communications

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023
Krung Thep Mahanakhon United States Naomi Eichenbaum Nivi Nehra Brad Rovin Division For Nephrology

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal
United States Krung Thep Mahanakhon Nivi Nehra Naomi Eichenbaum Brad Rovin European Union

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

SAN DIEGO, March 23, 2023 -- Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating... | March 23, 2023
Krung Thep Mahanakhon United States Nivi Nehra Naomi Eichenbaum Company Annual Report On Form European Union

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science